Vir Biotechnology (VIR) Total Current Liabilities (2018 - 2026)

Vir Biotechnology has reported Total Current Liabilities for 9 years, with the latest figure at $73.6 million in Q1 2026.

• Quarterly Total Current Liabilities fell 46.42% year-over-year to $73.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.6 million (down 46.42% YoY) and the FY2025 annual result came in at $92.8 million, down 22.44% from the prior year.
• Total Current Liabilities retreated to $73.6 million in Q1 2026 per VIR's latest filing, from $92.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $702.4 million in Q1 2022 and troughed at $73.6 million in Q1 2026.
• A 5-year average of $233.1 million and a median of $137.3 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities surged 227.25% in 2022, then slumped 80.62% in 2024.
• Over 5 years, Total Current Liabilities stood at $511.0 million in 2022, then plunged by 65.68% to $175.4 million in 2023, then tumbled by 31.78% to $119.7 million in 2024, then retreated by 22.44% to $92.8 million in 2025, then decreased by 20.75% to $73.6 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $73.6 million, $92.8 million, and $75.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.